Court rules against Liquidia in United Therapeutics patent fight
A Delaware court upheld United Therapeutics' patent claims on Yutrepia, sending Liquidia shares down sharply.
Palanor Wire · composed from 3 outlets · every claim links to its sources
What happened
A US federal court ruled against Liquidia Corporation in a patent dispute with United Therapeutics on September 30, 2026. 1456 The US District Court of Delaware upheld United Therapeutics' patent claims on Yutrepia. 56 Liquidia's stock price fell roughly 50% to 57% following the ruling. 135 United Therapeutics' stock price jumped nearly 13% after the favorable ruling. 2
Why it matters
The ruling puts fresh pressure on the commercial outlook for Liquidia's key drug, Yutrepia. 1 The patent dispute had been long-running between the two companies. 16
Sources · 7
[1]United Therapeutics (UTHR) Shares Surge 13% After Favorable Patent Ruling on Yutrepia
gurufocus.com · via Marketaux
[2]Why is Liquidia stock plunging? Yutrepia patent case explained - Liquidia Stock Plunges Nearly 50%
economictimes.indiatimes.com · via Marketaux
[3]Liquidia Corp (LQDA) Shares Plunge 25% After Patent Dispute Court Ruling
gurufocus.com · via Marketaux
[4]Liquidia Corp (LQDA) Shares Plunge Over 57% Following Patent Ruling on YUTREPIA
gurufocus.com · via Marketaux
[5]Delaware Court Rules Liquidia (LQDA) Infringed United Therapeutics Patent on Yutrepia
gurufocus.com · via Marketaux
[6]Liquidia (LQDA) Shares Drop 52% After Delaware Court Patent Ruling
gurufocus.com · via Marketaux
[7]Liquidia slumps after US court rules for United Therapeutics in patent fight reut.rs/4yo18Bo
Reuters · Bluesky
Matched signals
Lattice signals Numen pinned to this story at publish time.
No matched signals on this story.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →On X right now
Top engagement posts about this topic, ranked by likes + retweets + quotes.
No high-engagement X posts captured for this topic. Either the topic is too quiet or the upstream API was unavailable when this article published.
Unlock the analytical widgets on every article — signal matches, Trends snapshots, X overlays, agent reasoning — with a Member account.
Upgrade →Your read
How did this article land?
Three sliders. Optional comment. Anonymous is fine.
Open to anyone. One response per reader.